More than two dozen big buyers of prescription medicines expect that prices will rise by an average of 7% annually over the next three years, a slight uptick from a year ago. And 38% believe that a “substantial portion” or three quarters, of the anticipated increases can be attributed to a shift to higher-priced, newer therapies, up sharply from 13% a year ago, according to a new survey.

Interestingly, projections for price hikes over the next three years are actually flat on a weighted average basis, which represents a reversal in a decades-long trend. But there is a caveat. This change is driven primarily by just one respondent — a very large purchaser that is effectively an outlier.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Looks like their previous predictions were inaccurate and unreliable. Why should we believe the latest wild guesses?

    • Hi Adam
      No reason to believe any one person’s crystal ball, but as a window into sentiment, the temperature reading is interesting. And there’s also the take on biosimilar adoption.
      ed at pharmalot

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy